Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.

Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST.

Cancer Discov. 2012 Jul;2(7):591-7. doi: 10.1158/2159-8290.CD-12-0028. Epub 2012 Jun 15.

2.

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardin A, Mercher T, Gaulard P, Nyga R, Jeziorowska D, Douay L, Vainchenker W, Louache F, Gespach C, Solary E, Coppo P.

Leukemia. 2014 Feb;28(2):338-48. doi: 10.1038/leu.2013.157. Epub 2013 May 21.

PMID:
23689514
3.

Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.

Guo Y, Arakawa F, Miyoshi H, Niino D, Kawano R, Ohshima K.

Pathol Int. 2014 Jun;64(6):263-6. doi: 10.1111/pin.12166.

PMID:
24965108
4.

Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.

Sibbesen NA, Kopp KL, Litvinov IV, Jønson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Iversen L, Bonefeld CM, Geisler C, Woetmann A, Odum N.

Oncotarget. 2015 Aug 21;6(24):20555-69.

5.

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.

Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, Janik JE, Jacobson S, Waldmann TA.

Blood. 2011 Feb 10;117(6):1938-46. doi: 10.1182/blood-2010-09-305425. Epub 2010 Nov 24.

6.

JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications.

de Martino M, Gigante M, Cormio L, Prattichizzo C, Cavalcanti E, Gigante M, Ariano V, Netti GS, Montemurno E, Mancini V, Battaglia M, Gesualdo L, Carrieri G, Ranieri E.

Urol Oncol. 2013 Aug;31(6):930-7. doi: 10.1016/j.urolonc.2011.07.001. Epub 2011 Aug 24.

PMID:
21868263
7.

Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.

Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K, Taniguchi Y, Sekine M, Kamiunntenn A, Maeda K, Nagata K, Matsunaga T, Shimoda K.

Int J Hematol. 2010 Sep;92(2):320-5. doi: 10.1007/s12185-010-0653-2. Epub 2010 Aug 10.

PMID:
20697856
8.

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ.

Oncogene. 2015 Jun 4;34(23):2991-9. doi: 10.1038/onc.2014.243. Epub 2014 Aug 11.

9.

Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, Behrmann I, Zerwes HG.

Chem Biol. 2011 Mar 25;18(3):314-23. doi: 10.1016/j.chembiol.2011.01.012.

10.

A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.

Oh K, Joo KM, Jung YS, Lee J, Kang H, Lee HY, Lee DS.

J Immunol Methods. 2010 Mar 31;354(1-2):45-52. doi: 10.1016/j.jim.2010.01.010. Epub 2010 Feb 4.

PMID:
20138049
11.

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, Zhao L, Herling M, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Aug 28;124(9):1460-72. doi: 10.1182/blood-2014-03-559542. Epub 2014 May 13.

13.

Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.

Zhang Q, Lee B, Korecka M, Li G, Weyland C, Eck S, Gessain A, Arima N, Lessin SR, Shaw LM, Luger S, Kamoun M, Wasik MA.

Leuk Res. 1999 Apr;23(4):373-84.

PMID:
10229324
14.

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J.

Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.

15.

A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

Kim BH, Yin CH, Guo Q, Bach EA, Lee H, Sandoval C, Jayabose S, Ulaczyk-Lesanko A, Hall DG, Baeg GH.

Mol Cancer Ther. 2008 Sep;7(9):2672-80. doi: 10.1158/1535-7163.MCT-08-0309.

16.

Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.

Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC.

J Biol Chem. 2009 Mar 13;284(11):6773-81. doi: 10.1074/jbc.M807531200. Epub 2009 Jan 12.

17.

Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation.

Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA.

J Biol Chem. 2010 Feb 5;285(6):3582-91. doi: 10.1074/jbc.M109.053843. Epub 2009 Nov 18.

18.

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Davé UP.

Blood. 2011 Oct 6;118(14):3911-21. doi: 10.1182/blood-2010-12-319467. Epub 2011 Aug 5.

19.
20.

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.

Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, Huang JY, Wang L, Shen Y, Meng G, Zhou JF, Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z, Peng ZG, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi JY, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao WL, Chen Z, Chen SJ.

Nat Genet. 2015 Sep;47(9):1061-6. doi: 10.1038/ng.3358. Epub 2015 Jul 20.

PMID:
26192917
Items per page

Supplemental Content

Write to the Help Desk